Table 2.
Treatment | Months follow-up (range) | Number of studies | Number of patients | Mean symptom improvementa % (range) | Mean prevalencea of GER (range) | ||
---|---|---|---|---|---|---|---|
No ARP | With ARP | No ARP | With ARP | ||||
Transthoracic myotomy | 102.0 (57–172) | 13 | 842 | 85.1 (66–97) | 80.2 (66–97) | 29.2 (4–66) | 13.6 (0–28) |
Thoracoscopic myotomy | 36.4 (12–72) | 8 | 211 | 77.6 (31–94) | n/a | 28.3 (15–60) | n/a |
Transabdominal myotomy | 87.4 (8–190) | 10 | 732 | 64.4 (57–66) | 89.7 (73–100) | 28.5 (21–64) | 7.5 (0–15) |
Laparoscopic myotomy | 35.4 (8–83) | 39 | 3,086 | 89.9 (86–100) | 90.3 (77–100) | 31.5 (11–60) | 8.8 (0–44) |
ARP antireflux procedure, n/a data not collected for at that time points in the studies used to compile the meta-analysis, GER postprocedure gastroesophageal reflux symptoms
aWeighted averages of the sample prevalence in each of the studies, with weights equal to the number of patients